Cell culture method and product producing method

By adjusting poloxamer concentrations and viscosities in foam solutions during cell culture, aggregate formation is prevented, ensuring continuous operation and efficient oxygen supply in high-density cell cultures.

WO2024248118A1PCT designated stage expired Publication Date: 2024-12-05FUJIFILM CORP
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
PCT/JP2024/019988
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-31
Filing Date
2024-05-31
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

High poloxamer concentrations in foam solutions during cell culture lead to the formation of aggregates, which clog filtration membranes and disrupt continuous production, especially in high-density cell cultures where sufficient oxygen supply is critical.

Method used

Adjusting the poloxamer concentration in the foam liquid to be six times or less than in the culture solution, or maintaining the viscosity of the foam liquid at 1.5 mPa·s or less under specific temperature conditions, along with controlled aeration and foam management, to prevent aggregate formation.

Benefits of technology

This approach effectively suppresses the generation of aggregates in the foam, maintaining the desired culture period and preventing filtration membrane clogging, thus ensuring continuous and efficient cell culture operations.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure JPOXMLDOC01-APPB-T000001
    Figure JPOXMLDOC01-APPB-T000001
  • Figure 00000028_0000
    Figure 00000028_0000
Patent Text Reader

Abstract

The present invention addresses the problem of providing a cell culture method and a product producing method in both of which the formation of aggregates in foam is suppressed. The present invention provides a cell culture method in which cells are cultured in a liquid culture medium at a cell density of 30×106 cells / mL to 400×106 cells / mL inclusive, the method including: a step A in which the poloxamer concentration in a foam solution constituting foam is adjusted to a value not more than 6-times the poloxamer concentration in the liquid culture medium; or a step B in which the viscosity of the foam solution constituting the foam is adjusted to 1.5 mPa・s or less under the conditions where the temperature is 35°C to 38°C inclusive.
Need to check novelty before this filing date? Find Prior Art

Description

Cell culture method and product manufacturing method

[0001] The present invention relates to a cell culture method and a method for producing a product, in which cells are cultured so that the poloxamer concentration or viscosity of the foam liquid satisfies a predetermined condition.

[0002] Cell culture is carried out for the purpose of increasing the number of cells with useful properties or for producing products from cells. High-density cell culture (e.g., a cell density of 120 × 10 6 At a cell density (cells / mL), it is necessary to ensure sufficient oxygen supply to cells. kLa is generally known as an oxygen supply index, and kLa is also used as an oxygen supply index during scale-up. In other words, it is desirable to design a system so that the same kLa as at a small scale can be achieved even when scaled up. For example, providing sufficient stirring power is known as a means of improving kLa. On the other hand, stirring can cause shear damage to cells. Particularly in scale-up systems, increasing the stirring speed to increase the stirring power increases shear caused by the rotation of the stirring blades, resulting in greater damage to cells. One way to suppress shear damage to cells due to stirring, etc., is to add an additive with a cytoprotective effect to the culture medium. A typical additive with a cytoprotective effect is poloxamer (a surfactant). A low poloxamer concentration in the culture medium increases cell damage.

[0003] Patent Document 1 describes a method for recovering a recombinant protein, the method comprising the steps of: (1) establishing a cell culture by seeding a bioreactor with mammalian cells expressing the recombinant protein; (2) maintaining the cell culture by perfusing the cell culture with fresh cell culture medium formulated or supplemented to achieve a nonionic block copolymer concentration of 1 g / L and passing the cell culture through a hollow fiber filter having a pore size or molecular weight cutoff that retains the recombinant protein in the bioreactor, and collecting the permeate; (3) once predetermined parameters are reached, perfusing the cell culture with fresh cell culture medium formulated or supplemented to achieve a nonionic block copolymer concentration of 5 g / L and passing the cell culture through a hollow fiber filter having a pore size or molecular weight cutoff that does not retain the recombinant protein in the bioreactor; and (4) collecting the permeate containing the recombinant protein.

[0004] In Patent Document 2, a gas is introduced into the culture solution in a culture tank, and 0.7 × 10 8 The present invention describes a cell culture method including a culture step of culturing a cell suspension having a cell density of 1000 cells / mL or more, and a membrane separation treatment step of passing the cell suspension extracted from the culture tank through a separation membrane to separate it into a cell-containing liquid and a permeate, wherein the amount of an antifoaming component added to the culture tank per unit culture liquid volume and per unit time is 0.70 mg / hour / L or less.

[0005] Patent No. 7097404 International Publication No. WO2023 / 054556

[0006] Gas aeration during cultivation causes foam to form at the top of the fermenter, and the poloxamer concentration in the foam was found to be higher than that in the culture solution. Furthermore, as the poloxamer concentration in the foam increases, cell-derived components (especially highly hydrophobic substances) in the foam aggregate, resulting in the formation and accumulation of aggregates. If these aggregates in the foam fall into the culture solution, the amount of aggregates in the culture solution increases, accelerating clogging of the filtration membrane in perfusion culture. This makes it impossible to maintain the desired culture period in continuous production. Therefore, it is important to suppress the increase in poloxamer concentration in the foam.

[0007] An object of the present invention is to provide a cell culture method and a product production method in which the generation of aggregates in the foam is suppressed.

[0008] As a result of intensive research to solve the above problems, the inventors discovered that the above problems can be solved by culturing cells in such a way that the poloxamer concentration or viscosity of the foam liquid satisfies certain conditions, and thus completed the present invention.

[0009] That is, the present invention provides the following inventions: <1> 30 × 10 in a culture medium 6 cells / mL or more 400×10 6A cell culture method for culturing cells at a cell density of 1000 cells / mL or less, comprising: Step A: adjusting the poloxamer concentration of a foam liquid constituting the foam to be 6 times or less the poloxamer concentration in the culture solution; or Step B: adjusting the viscosity of the foam liquid constituting the foam to be 1.5 mPa s or less under conditions of 35° C. to 38° C. <2> The cell culture method according to <1>, wherein Step A is performed when the poloxamer concentration of the foam liquid constituting the foam is 6 times or more the poloxamer concentration in the culture solution, or Step B is performed when the viscosity of the foam liquid constituting the foam is 1.5 mPa s or more under conditions of 35° C. to 38° C. <3> The cell culture method according to <1> or <2>, wherein the poloxamer concentration in the culture solution is 1.5 g / L or more and 15 g / L or less. <4> The cell culture method according to any one of <1> to <3>, wherein the step A or the step B includes a step of aerating a gas into the culture solution. <5> The cross-sectional area of ​​the gas-liquid interface of the culture vessel is S [cm 2 ], and the total amount of gas aeration into the culture medium is V [cm 3 / min] and the height of the foam layer is H [cm], H, S, and V satisfy the relationship: H / (V / S) < 25 min. 2 ], and the total amount of gas aeration into the culture medium is V [cm 3 / min], S and V satisfy the relationship 0.3 cm / min < V / S < 9.4 cm / min. <7> The cell culture method according to any one of <1> to <6>, wherein step A or step B comprises spraying, dropping or sprinkling a liquid onto the foam. <8> The cell culture method according to any one of <1> to <6>, wherein step A or step B comprises removing the foam. <9> The cell culture method according to <8>, wherein the removing the foam is a step of eliminating the foam or incorporating the foam into the culture solution by rotating a stirring blade. <10> A method for producing a product, comprising carrying out the cell culture method according to any one of <1> to <9>. <11> The method according to <10>, wherein the product is a protein. <12> The method according to <13>, wherein the cell culture method comprises culturing 30 x 10 6cells / mL or more 400×10 6 1. A method for producing a product, comprising culturing cells at a cell density of 1000 cells / mL or less, the method comprising: Step A: adjusting the poloxamer concentration of a foam liquid constituting the foam to 6 times or less the poloxamer concentration in the culture solution; or Step B: adjusting the viscosity of the foam liquid constituting the foam to 1.5 mPa s or less under conditions of 35°C or higher and 38°C or lower.

[0010] According to the cell culture method and the method for producing a product of the present invention, the occurrence of aggregates in the foam can be suppressed.

[0011] FIG. 1 shows a cell culture device.

[0012] The present invention will be described in detail below. In this specification, a numerical range indicated using "to" means a range that includes the numerical values ​​before and after "to" as the minimum and maximum values, respectively.

[0013] In the cell culture method of the present invention, 30 × 10 6 cells / mL or more 400×10 6 The cell culture method involves culturing cells at a cell density of 1000 cells / mL or less, the method comprising: Step A: adjusting the poloxamer concentration of a foam liquid constituting the foam to 6 times or less the poloxamer concentration in the culture medium; or Step B: adjusting the viscosity of the foam liquid constituting the foam to 1.5 mPa s or less under conditions of 35°C or higher and 38°C or lower.

[0014] The culture medium contains both cells and culture supernatant. In the present invention, the cell density of the culture medium is 30 × 10 6 cells / ml or more 400×10 6 cells / ml or less, 30 x 10 6 cells / ml or more 300×10 6 cells / ml or less, and preferably 80 x 10 6 cells / ml or more 240×10 6 More preferably, it is 80 x 10 cells / ml or less. 6 cells / ml or more 200×106 More preferably, it is 80 x 10 cells / ml or less. 6 cells / ml or more 160×10 6 More preferably, the concentration is 100×10 6 cells / ml or more 160×10 6 More preferably, the concentration is 100×10 6 cells / ml or more 120×10 6 It is particularly preferable that the concentration is 10 cells / ml or less. 6 It is sometimes written as M instead of .

[0015] The cell density can be measured by a viable cell analyzer, Vi-CELL XR, manufactured by Beckman Coulter.

[0016] In the present invention, step A is carried out to adjust the poloxamer concentration in the foam liquid constituting the foam to be 6 times or less the poloxamer concentration in the culture solution, or step B is carried out to adjust the viscosity of the foam liquid constituting the foam to be 1.5 mPa s or less under conditions of 35° C. to 38° C. Both steps A and B are intended to prevent an increase in the poloxamer concentration in the foam liquid constituting the foam.

[0017] The poloxamer concentration in the foam liquid and the poloxamer concentration in the culture medium can be measured by centrifuging the foam liquid or culture medium at 300 G for 15 minutes, collecting the centrifugal supernatant, and measuring the liquid viscosity using high performance liquid chromatography (HPLC). The viscosity of the foam liquid can be measured by centrifuging the foam liquid at 300 G for 15 minutes, collecting the centrifugal supernatant, heating it to 37°C in a warm bath, and measuring the liquid viscosity using a viscometer. For example, a vibration viscometer (VM-10A-H manufactured by Sekonic) can be used as the viscometer.

[0018] Preferably, step A can be carried out when the poloxamer concentration in the foam liquid constituting the foam is 6 times or more the poloxamer concentration in the culture solution, or step B can be carried out when the viscosity of the foam liquid constituting the foam is 1.5 mPa·s or more under conditions of 35° C. to 38° C. As a result, the poloxamer concentration in the foam liquid constituting the foam can be maintained at 6 times or less the poloxamer concentration in the culture solution, or the viscosity of the foam liquid constituting the foam can be maintained at 1.5 mPa·s or less under conditions of 35° C. to 38° C.

[0019] The poloxamer concentration in the culture medium is preferably 1.5 g / L or more and 15 g / L or less. Poloxamer has a cytoprotective effect. From the viewpoint of suppressing aggregates, the poloxamer concentration in the culture medium is preferably 1.5 g / L or more and less than 6 g / L (preferably 2.0 g / L or more and 5.8 g / L or less, more preferably 3.0 g / L or more and 5.5 g / L or less, and even more preferably 4.0 g / L or more and 5.5 g / L or less). From the viewpoint of cytoprotective effect, the poloxamer concentration in the culture medium is preferably 6 g / L or more and 15 g / L or less (preferably 7 g / L or more and 14 g / L or less, more preferably 8 g / L or more and 13 g / L or less, and even more preferably 9 g / L or more and 12 g / L or less). In this case, the amount of aggregates increases, but this is effectively suppressed by the present invention.

[0020] Step A or step B preferably includes a step of bubbling a gas into the culture medium.

[0021] The cross-sectional area of ​​the gas-liquid interface of the culture tank is S [cm 2 ], and the total amount of gas aeration into the culture medium is V [cm 3 / min] and the height of the foam layer is H [cm], H, S, and V preferably satisfy H / (V / S) < 25 min, more preferably satisfy H / (V / S) < 20 min, even more preferably satisfy H / (V / S) < 16 min, and particularly preferably satisfy H / (V / S) < 10 min.

[0022] The lower limit of H / (V / S) is not particularly limited, but is generally 1 min or more.

[0023] The cross-sectional area of ​​the gas-liquid interface of the culture tank is S [cm 2 ], and the total amount of gas aeration into the culture medium is V [cm 3 / min], S and V preferably satisfy 0.3 cm / min < V / S < 9.4 cm / min, more preferably 1.0 cm / min < V / S < 9.4 cm / min, and even more preferably 2.9 cm / min < V / S < 9.4 cm / min.

[0024] Cross-sectional area S [cm 2 ] can be calculated based on the inner diameter of the culture tank. The total amount of gas aeration into the culture solution V [cm 3 / min] is based on the set amount of gas aeration in the gas supply means. The height H [cm] of the foam layer is the average value at the cross section of the culture tank. The average value is calculated by measuring the height at any three points and averaging the three points.

[0025] Step A or step B may include a step of spraying, dripping, or sprinkling a liquid onto the foam. By spraying, dripping, or sprinkling a liquid onto the foam, the poloxamer concentration of the foam liquid constituting the foam or the viscosity of the foam liquid constituting the foam can be reduced. When spraying, dripping, or sprinkling a liquid, the liquid may be sprayed, dripped, or sprinkled from the top of the culture tank, but is not particularly limited thereto.

[0026] Step A or step B may include a step of removing foam. Removing foam can also reduce the poloxamer concentration of the foam liquid constituting the foam or the viscosity of the foam liquid constituting the foam. The step of removing foam may be, for example, a step of removing the foam or incorporating the foam into the culture solution by rotating a stirring blade, but is not particularly limited thereto. It is preferable to position the stirring blade in a position that allows it to come into contact with the foam. Specifically, the stirring blade can be positioned in the culture vessel near the top of the culture solution.

[0027] In the cell culture method of the present invention, when the cell density reaches a predetermined cell density, it is preferable to remove the culture medium containing the cells from the culture tank (bleeding) so that the cell density is maintained at the predetermined cell density.

[0028] Bleeding can be performed by any method as long as the culture solution containing the cells can be removed from the culture vessel. For example, as shown in Figure 1, a pipe for discharging the culture solution can be inserted into the culture solution, and the culture solution can be discharged from the culture vessel through the pipe.

[0029] Preferably, the culture medium may be bled while measuring the capacitance of the culture medium in-line. In-line measurement refers to measuring some measurement value that indicates the state of the culture medium while cell culture is being performed. To measure the capacitance in-line, for example, as shown in FIG. 1, a capacitance sensor may be inserted into the culture medium, and the capacitance of the culture medium may be measured in-line during culture.

[0030] Preferably, the bleeding may be automatically controlled. Automatic control means that the start and stop of bleeding are automatically controlled based on some measured value indicating the state of the culture solution. For example, the start and stop of bleeding can be automatically controlled based on a measured value of the capacitance of the culture solution.

[0031] Preferably, bleeding may be performed so that the variation in the capacitance of the culture medium measured inline is ±20% or less of the average capacitance during the production period. The variation in the capacitance of the culture medium measured inline is more preferably ±15% or less of the average capacitance during the production period, even more preferably ±12% or less of the average capacitance during the production period, and particularly preferably ±8% or less of the average capacitance during the production period. The lower limit of the variation in the capacitance of the culture medium is not particularly limited, and it is sufficient if it is 0% or more, but considering daily fluctuations in cell growth, variation of 0.1% or more will actually occur.

[0032] An example of bleeding can be performed by the steps of: (i) setting a target capacitance; (ii) setting a weight control value for the culture vessel; (iii) measuring the capacitance of the culture solution at a period of 0.1 seconds or less; (iv) when the capacitance of the culture solution exceeds the target, operating a pump that extracts the culture solution at a speed of 0.3 vvd to 3 vvd (where vvd means volume of culture solution extracted / volume of culture solution / day); (v) automatically supplying medium to the culture vessel while measuring the mass of the culture solution so that the fluctuation in the liquid volume of the culture solution is within 10%; and (vi) stopping the pump that extracts the culture solution when the capacitance of the culture solution falls below the target by 0.01% or more.

[0033] An example of a cell culture device that can be used for culturing cells in the present invention is shown in Figure 1. In Figure 1, a culture vessel 10 is a vessel that contains a culture medium containing cells. Cells are cultured in the culture medium inside the culture vessel 10.

[0034] Oxygen and / or air is sent from the sparger air supply pipe 1 and introduced into the culture solution through a sparger 11 having a pore size of 20 μm. The dissolved oxygen concentration in the culture solution can be adjusted by the sparger 11. The sparger is not particularly limited, but for example, a sparger having an average pore size of 1 μm or more and 300 μm or less in the gas release section and releasing a gas containing 30% or more by volume of oxygen can be used.

[0035] Air and / or carbon dioxide is introduced from the air supply pipe 2 into the upper part of the culture solution inside the culture vessel. Culture medium is supplied to the culture vessel from the culture medium supply pipe 3. A culture medium supply pump 15 is provided on the culture medium supply pipe 3. The exhaust pipe 4 is a pipe for exhausting air, and an exhaust filter 5 is connected to its end. The sampling pipe 6 is a pipe for collecting (sampling) the culture solution. The bleeding pipe 7 is a pipe for extracting (bleeding) the culture solution. A capacitance sensor 8 is attached so as to come into contact with the culture solution inside the culture vessel. A dissolved oxygen sensor 9 is attached so as to come into contact with the culture solution inside the culture vessel.

[0036] A stirring member having a stirring blade 12 may be provided inside the culture vessel 10. By rotating the stirring blade 12, the culture solution inside the culture vessel 10 is stirred, maintaining the homogeneity of the culture solution. The stirring of the culture solution by the stirring blade 12 also stirs the bubbles released by the sparger. The position of the stirring member having the stirring blade, the size of the stirring blade, etc. are not particularly limited and may be designed depending on the cell type used, the amount of culture solution, the amount of oxygen supplied, the position, number, size, etc. of the sparger. Furthermore, in order to quickly stir the bubbles coming out of the sparger and prevent the bubbles from coalescing, it is preferable to position the stirring blade 12 close to the sparger. Figure 1 shows the presence of foam 19.

[0037] A perfusion device 13 is connected to the bottom of the culture vessel 10. The culture solution inside the culture vessel 10 passes through the perfusion device 13 (hollow fiber MF membrane), and the permeate containing the cell product is removed from the culture vessel 10 by a delivery pump 16. The flow of the permeate is indicated by arrows 14. The perfusion device 13 may be equipped with a pressure gauge 17 and a diaphragm pump 18.

[0038] In the present invention, the cell suspension removed from the culture vessel may be passed through a separation membrane to separate it into a cell-containing solution and a permeate. This operation can be performed using a perfusion device. In this operation, the cell suspension removed from the culture vessel is separated into a cell-containing solution having a higher cell density than the cell suspension and a permeate having a lower cell density than the cell suspension. The cell density can be measured using a Vi-CELL XR viable cell analyzer manufactured by Beckman Coulter.

[0039] The membrane separation process is preferably tangential filtration, more preferably alternating tangential flow (ATF) or tangential flow, and most preferably alternating tangential flow. Filters capable of performing alternating tangential flow include SuATF10-S02PES and F2 RF02PES manufactured by Repligen.

[0040] As a medium for cell culture, a medium that is commonly used for culturing animal cells can be used. For example, CD OptiCHO (ThermoFisher), Dulbecco's Modified Eagle's Medium (DMEM), Eagle's Minimum Essential Medium (MEM), RPMI-1640 medium, RPMI-1641 medium, F-12K medium, Ham's F12 medium, Iscove's Modified Dulbecco's Medium (IMDM), McCoy's 5A medium, Leibovitz's L-15 medium, and EX-CELL™ 300 series (JRH Biosciences), CHO-S-SFMII (Invitrogen), CHO-SF (Sigma-Aldrich), CD-CHO (Invitrogen), IS CHO-V (Irvine Scientific), PF-ACF-CHO (Sigma-Aldrich), etc. may be used. Alternatively, a self-made medium may be used.

[0041] The medium may be supplemented with serum, such as fetal calf serum (FCS), or serum-free. The medium may be supplemented with additional components, such as amino acids, salts, sugars, vitamins, hormones, growth factors, buffers, antibiotics, lipids, trace elements, plant protein hydrolysates, etc. Protein-free media may also be used.

[0042] The pH of the medium varies depending on the cells to be cultured, but is generally pH 6.0 to 8.0, preferably pH 6.4 to 7.6, and more preferably pH 6.7 to 7.4. The culture temperature is generally 30°C to 40°C, preferably 32°C to 39°C, and more preferably 36°C to 38°C, and the culture temperature may be changed during culture. The culture is carried out under CO 2 The process can be carried out in an atmosphere having a concentration of 0 to 40% by volume, preferably 2 to 25% by volume, and more preferably 3 to 20% by volume.

[0043] The amount of culture medium is preferably 1 L or more, more preferably 50 L or more, and even more preferably 200 L or more.

[0044] The culture period is not particularly limited, but is the same as the period for perfusion culture described below. In the present invention, the culture period is preferably 14 days or longer.

[0045] During the culture, the medium can be replaced, aerated, or stirred as necessary. When stirring is performed during the culture, the stirring speed is not particularly limited, but the stirring power per unit volume is generally 10 to 300 kW / m 3 and preferably 20 to 200 kW / m 3 and more preferably 30 to 100 kW / m 3 is.

[0046] The dissolved oxygen concentration in the culture solution can be set appropriately and is not particularly limited, but is generally 20 to 150%, preferably 30 to 120%, and more preferably 30 to 100%, when the saturated dissolved oxygen concentration in air at 1 atmosphere at 37°C is taken as 100%.

[0047] Cell culture can be carried out using a cell culture device having the configuration described above in this specification. The cell culture device may be any of a fermenter-type tank culture device, an airlift-type culture device, a culture flask-type culture device, a spinner flask-type culture device, a microcarrier-type culture device, a fluidized bed-type culture device, a hollow fiber-type culture device, a roller bottle-type culture device, or a packed tank-type culture device. From the viewpoint of homogenizing the culture environment, the culture vessel is preferably a single-use culture tank. From the viewpoint of homogenizing the culture environment, the cell culture device may also be a single-use culture tank.

[0048] The viscosity of the culture medium is preferably 1.2 mPa·s or more and less than 15 mPa·s, more preferably 1.4 mPa·s or more and less than 12 mPa·s, and particularly preferably 1.6 mPa·s or more and less than 10 mPa·s.

[0049] In the present invention, a pH adjuster may be added during the culture. In view of clogging of the filtration channel, the amount of pH adjuster added to the culture tank per day is preferably 8 mmol / day / L or less, more preferably 7 mmol / day / L or less. However, it is not necessary to add a pH adjuster. The pH adjuster is not particularly limited, but examples thereof include Na 2 CO 3 aqueous solution, aqueous NaOH or NaHCO 3 An aqueous solution is preferred, more preferably NaHCO 3 The pH adjuster may be added alone or mixed with the medium or antifoaming agent. To avoid local pH fluctuations in the culture solution due to the addition of the pH adjuster, it is preferable to add the pH adjuster to the medium.

[0050] In the present invention, the preferred mode of cell culture is perfusion culture. Perfusion culture is a culture method in which fresh medium is added and spent medium is simultaneously removed. Perfusion culture generally allows for a high viable cell density to be achieved. A typical perfusion culture begins with a batch culture start-up lasting one or two days, after which fresh feed medium is continuously, stepwise, and / or intermittently added to the culture, and spent medium is simultaneously removed. In perfusion culture, spent medium can be removed while maintaining viable cell density using methods such as sedimentation, centrifugation, or filtration. An advantage of perfusion culture is that the culture in which the target protein is produced can be maintained for a longer period of time than batch or fed-batch culture.

[0051] Perfusion can be continuous, stepwise, intermittent, or a combination thereof, preferably continuous. The animal cells are maintained in culture, and the removed spent medium may be substantially cell-free or contain far fewer cells than the culture. The product expressed by the cell culture can be maintained in culture or recovered by selecting the membrane pore size.

[0052] The period of perfusion culture is preferably 5 to 150 days, more preferably 10 to 100 days, and even more preferably 20 to 90 days. A culture period of 5 days or more is preferred because it increases the number of cells obtained and, if the cells produce a product, increases the amount of product produced. A culture period of 150 days or less is preferred from the viewpoint of preventing clogging of the filtration membrane used in perfusion culture and preventing contamination.

[0053] The perfusion ratio is not particularly limited, but is generally 0.3 vvd to 5.0 vvd, preferably 0.5 vvd to 3.0 vvd, and more preferably 0.8 vvd to 2.5 vvd. The "vvd" in the perfusion ratio refers to the volume of culture medium extracted / volume of culture medium in the culture vessel / day. Note that the perfusion ratio referred to here is a different parameter from the example of bleeding, "(iv) When the capacitance of the culture medium exceeds the target, operate the pump extracting the culture medium at a speed of 0.3 vvd to 3 vvd."

[0054] The culture medium is usually removed from the culture vessel using a pump, but other available liquid-transporting means may also be used. The culture medium removed from the culture vessel is then subjected to treatments such as product recovery and dead cell removal. After product recovery and dead cell removal, the culture medium removed from the culture vessel may be partially discarded or returned to the culture vessel. If a loss of medium occurs due to the above treatments, it can be compensated for by, for example, supplying fresh medium to the culture vessel.

[0055] The type of cell used in the present invention is not particularly limited, and examples include animal cells, plant cells, eukaryotic cells such as yeast, prokaryotic cells such as Bacillus subtilis, and Escherichia coli. The cells are preferably animal cells (more preferably mammalian cells) or insect cells, and most preferably mammalian cells. The cells may be primary cells or established cell lines.

[0056] Examples of cells include Chinese hamster ovary (CHO) cells, HEK cells (human embryonic kidney-derived cells), BHK cells, 293 cells, C127 cells, myeloma cells (such as NS0 cells), PerC6 cells, SP2 / 0 cells, hybridoma cells, COS cells (African green monkey kidney-derived cells), 3T3 cells, HeLa cells, Vero cells (African green monkey kidney epithelial cells), MDCK cells (canine kidney tubular epithelial cells), PC12 cells, and WI38 cells. The cells may also be stem cells such as embryonic stem cells (ES cells) or induced pluripotent stem cells (iPS cells). Among these, CHO cells, HEK cells, BHK cells, and hybridoma cells are preferred, CHO cells and HEK cells are more preferred, and CHO cells are most preferred. CHO cells are widely used for the production of recombinant proteins, such as cytokines, coagulation factors, and antibodies. It is preferable to use dihydrofolate reductase (DHFR)-deficient CHO cells, and for example, CHO-DG44 can be used as the DHFR-deficient CHO cells.

[0057] The higher the cell viability, the better, with 80% or more being preferred, 85% or more being more preferred, 90% or more being particularly preferred, and 95% or more being most preferred.

[0058] These cells may be cells into which a foreign gene encoding a protein to be expressed (e.g., an antibody) has been introduced. Preferably, the cells are antibody-producing cells. An expression vector can be used to introduce a foreign gene encoding a protein to be expressed into a cell. By introducing an expression vector containing DNA encoding the protein to be expressed, an expression regulatory sequence (e.g., an enhancer, a promoter, a terminator, etc.), and optionally a selection marker gene into a cell, a cell into which a foreign gene encoding the protein to be expressed has been introduced can be produced. There are no particular limitations on the expression vector, and it can be selected and used appropriately depending on the type of cell, purpose, etc.

[0059] Any promoter can be used as long as it is functional in mammalian cells. Examples include the promoter of the cytomegalovirus (CMV) IE (immediate early) gene, the SV40 early promoter, retrovirus promoters, metallothionein promoters, heat shock promoters, SRα promoters, and promoters and enhancers of Moloney murine leukemia virus. Furthermore, an enhancer of the human CMV IE gene may also be used together with the promoter.

[0060] Examples of selectable marker genes that can be used include drug resistance genes (neomycin resistance gene, DHFR gene, puromycin resistance gene, blasticidin resistance gene, hygromycin resistance gene, cycloheximide resistance gene), and fluorescent genes (genes encoding green fluorescent protein (GFP) or the like).

[0061] The method for introducing an expression vector into cells is not particularly limited, and for example, the calcium phosphate method, electroporation, liposome method, gene gun method, lipofection method, etc. can be used.

[0062] The method for producing a product according to the present invention is a method comprising carrying out the cell culture method of the present invention. In the method for producing a product according to the present invention, preferably, cells are cultured using a cell culture device to produce a product from the cells. That is, according to the present invention, 30 x 10 cells are cultured in a culture medium. 6 cells / mL or more 400×10 6 The present invention provides a method for producing a product, comprising culturing cells at a cell density of 1000 cells / mL or less, the method comprising: Step A: adjusting the poloxamer concentration of a foam liquid constituting the foam to 6 times or less the poloxamer concentration in the culture medium; or Step B: adjusting the viscosity of the foam liquid constituting the foam to 1.5 mPa s or less under conditions of 35°C or higher and 38°C or lower.

[0063] According to the present invention, there is provided a product produced by the method for producing a product according to the present invention.

[0064] In the present invention, the type of product is not particularly limited, but is preferably a protein. Examples of the product include recombinant polypeptide chains, recombinant secreted polypeptide chains, antigen-binding proteins, antibodies (e.g., human antibodies, humanized antibodies, chimeric antibodies, mouse antibodies, bispecific antibodies, etc.), Fc fusion proteins, fragmented immune immunoglobulins, single-chain antibodies (scFv), etc. In addition, the product may be an adenovirus, an adeno-associated virus, a lentivirus, etc.

[0065] The product is preferably an antibody, more preferably a human antibody, a humanized antibody, a chimeric antibody, or a mouse antibody. Examples of fragmented immune immunoglobulins include Fab, F(ab')2, and Fv. The class of the antibody is not particularly limited, and may be any class, such as IgG (e.g., IgG1, IgG2, IgG3, and IgG4), IgA, IgD, IgE, or IgM, although IgG and IgM are preferred for pharmaceutical use.

[0066] Human antibodies include all antibodies that have one or more variable and constant regions derived from human immunoglobulin sequences, hi one embodiment, all of the variable and constant domains are derived from human immunoglobulin sequences (fully human antibodies).

[0067] A humanized antibody has a sequence that differs from that of an antibody derived from a non-human species by one or more amino acid substitutions, deletions, and / or additions, such that the humanized antibody is less likely to provoke an immune response and / or provokes a less severe immune response when administered to a human subject compared to the non-human species antibody. In one example, certain amino acids within the framework and constant domains of the heavy and / or light chains of the non-human species antibody are mutated to produce a humanized antibody. In another example, constant domains from a human antibody are fused to variable domains of the non-human species.

[0068] A chimeric antibody is an antibody in which variable and constant regions of different origins are linked. For example, an antibody consisting of the heavy and light chain variable regions of a mouse antibody and the heavy and light chain constant regions of a human antibody is a mouse-human heterochimeric antibody. A recombinant vector that expresses a chimeric antibody can be produced by linking DNA encoding the variable region of a mouse antibody to DNA encoding the constant region of a human antibody and incorporating this into an expression vector. Recombinant cells transformed with the above vector are cultured to express the incorporated DNA, thereby obtaining the chimeric antibody produced during the culture.

[0069] Bispecific antibodies are antibodies that recognize two different antigen specificities. Various forms of bispecific antibodies exist. Reported methods for producing bispecific antibodies include linking two immunoglobulin molecules using crosslinkers such as N-succinimidyl 3-(2-pyridyldithiol) propionate or S-acetylmercaptosuccinic acid anhydride, or linking Fab fragments of immunoglobulin molecules. Bispecific antibodies can also be expressed by introducing genes encoding them into cells.

[0070] An Fc fusion protein refers to a protein having an Fc region, including antibodies. Fab is a monovalent fragment having the VL, VH, CL, and CH1 domains. F(ab')2 is a bivalent fragment having two Fab fragments linked by a disulfide bridge at the hinge region. An Fv fragment has the VL and VH domains of a single antibody arm. A single-chain antibody (scFv) is an antibody in which the VL and VH domains are joined via a linker (e.g., a synthetic sequence of amino acid residues) to form a continuous protein chain, where the linker is long enough to allow the protein chain to fold back on itself and form a monovalent antigen-binding site.

[0071] The antibody is not particularly limited, but examples thereof include an anti-IL-6 receptor antibody, an anti-IL-6 antibody, an anti-glypican-3 antibody, an anti-CD3 antibody, an anti-CD20 antibody, an anti-GPIIb / IIIa antibody, an anti-TNF antibody, an anti-CD25 antibody, an anti-EGFR antibody, an anti-Her2 / neu antibody, an anti-RSV antibody, an anti-CD33 antibody, an anti-CD52 antibody, an anti-IgE antibody, an anti-CD11a antibody, an anti-VEGF antibody, and an anti-VLA4 antibody.

[0072] The product may be recovered by simply recovering the culture medium, or by recovering the liquid from which at least a portion of the cells have been removed using, for example, a filter or a centrifuge, and any known method can be used without particular limitation. If it is desired to improve the purity of the product, change the solvent, or change the form, for example, to make it into a powder, the culture medium or the liquid can be subjected to further treatment.

[0073] It is also possible to collect a portion of the culture medium during perfusion, or to use a filter or centrifuge on a portion of the culture medium during perfusion, and collect the liquid from which at least a portion of the cells have been removed.

[0074] The product can be purified by a purification treatment. The obtained product can be purified to a high purity. Separation and purification of the product can be performed using separation and purification methods commonly used for proteins. For example, the product can be separated and purified by appropriately selecting and combining chromatography columns such as affinity chromatography, filters, ultrafiltration, salting out, dialysis, sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis, isoelectric focusing, etc., but is not limited to these. The concentration of the product obtained above can be measured by absorbance measurement or enzyme-linked immunosorbent assay (ELISA), etc. Furthermore, when the product is an antibody, the antibody titer can also be measured using a commercially available analytical instrument such as Roche's Cedex Bio.

[0075] Examples of columns used in affinity chromatography include protein A columns and protein G columns. Chromatography other than affinity chromatography includes, for example, ion exchange chromatography, hydrophobic chromatography, gel filtration, reverse phase chromatography, and adsorption chromatography. These chromatographies can be performed using liquid phase chromatography such as HPLC (high performance liquid chromatography) or FPLC (fast protein liquid chromatography).

[0076] The product can be modified or partially depeptidized by treating it with an appropriate polypeptide-modifying enzyme before or after purification, such as trypsin, chymotrypsin, lysyl endopeptidase, protein kinase, or glucosidase.

[0077] The products produced by the present invention can be used, for example, in biopharmaceuticals and regenerative medicine.

[0078] The present invention will be explained in more detail with reference to the following examples, but the present invention is not limited to these examples.

[0079] <Establishment of antibody-producing cells> A vector containing a nucleic acid sequence encoding IgG1 was constructed, and the constructed vector was introduced into CHO-DG44 cells to generate CHO-DG44 cells expressing IgG1 (IgG1 cells). The vector was constructed and introduced into the cells in accordance with Example 2 of JP-A-2016-517691. As described above, CHO cells producing monoclonal antibodies were prepared and used in the following experiments.

[0080] <Cell Culture> In the examples and comparative examples, experiments were carried out using the cell culture device shown in Figure 1. The culture medium was prepared with reference to the replacement medium in Table 2 of JP-A-2000-517188. A glass culture vessel with a diameter of 11.4 cm (cross-sectional area 102 cm) was used. 2 The medium (0.83 L) was poured into a glass culture vessel with a diameter of 22.5 cm (cross-sectional area 398 cm 2 The medium (7.1 L) was poured into a plastic culture tank with a diameter of 34.9 cm (cross-sectional area 957 cm 2 ) and the medium (50 L) was added.

[0081] 0.5 × 10 6 CHO cells were seeded at a concentration of 102 cells / mL. 2 In the case of a paddle with a diameter of 85 mm, the speed is 180 rpm and the cross-sectional area is 398 cm 2 In this case, a paddle with a diameter of 154 mm is used at 99 rpm, and the cross-sectional area is 957 cm 2In the case of , the propeller diameter was 111 mm and the rotation speed was 250 rpm. 2 Air and CO to a concentration of 5% 2 The total aeration volume was 0.01 vvm, and O was supplied from the bottom through a sparger installed in the culture tank so that the oxygen concentration in the culture solution was 80%. 2 After culturing on the second day after seeding, the medium was continuously supplied at a perfusion ratio of 0.6 vvd to the cells in a 102 cm cross-sectional area. 2 and a cross-sectional area of ​​398 cm 2 In this case, the cross-sectional area is 957 cm 2 using Repligen ATF2. 2 In the case of , the cell culture medium was continuously filtered using ATF4 manufactured by Repligen, and the collected solution was collected. Furthermore, on the fifth day, the perfusion ratio was changed to 1.2 vvd.

[0082] Thereafter, when the cell density reached the cell density shown in Table 1, the cell suspension was removed from the culture vessel at least once a day or continuously (bleeding), and the same amount of fresh medium was replenished to maintain the cell density at the cell density shown in Table 1. The period from the start of culture until the first start of bleeding was defined as the cell proliferation phase, and the period from the first start of bleeding was defined as the antibody production phase.

[0083] The culture conditions used here were set as shown in Table 1, and Examples 1 to 9 and Comparative Examples 1 to 4 were carried out. Thereafter, the culture was continued for 10 days or more, and the evaluations described below were carried out.

[0084] <Method for Automatic Cell Bleed Control> When cell bleeding was performed automatically, a FUTURA sensor manufactured by ABER was used to monitor the capacitance of the culture solution while automatically and continuously performing cell bleeding. Specifically, this was performed using the following method. (1) A target capacitance was set. (2) A weight control value for the culture tank was set. (3) The capacitance of the culture solution was measured at intervals of 0.1 s or less. (4) When the capacitance of the culture solution exceeded the target, the pump that extracts the culture solution was operated at a speed of 0.3 vvd to 3 vvd. (5) The culture medium was automatically supplied into the culture tank while measuring the weight of the culture tank so that the volume of the culture solution remained roughly constant. (6) When the capacitance of the culture solution fell 0.01% or more below the target, the pump that extracts the culture solution was stopped.

[0085] [Measurement and evaluation methods] <Method for collecting foam liquid> The foam is drawn from a sterilized tube placed in the culture tank, and the liquefied foam is used as the foam liquid. When the height of the foam layer in the culture tank is 6 cm or more, the foam liquid is drawn from a position approximately 3 cm below the top of the foam layer. When the height of the foam layer is less than 6 cm, the foam liquid is drawn from approximately the center of the height of the foam layer (the center between the culture liquid surface and the foam layer surface).

[0086] <Method for measuring poloxamer concentration in foam> The foam is centrifuged at 300 G for 15 minutes, the supernatant is collected, and the poloxamer concentration is measured by HPLC.

[0087] <Method for measuring viscosity of foam liquid> The foam liquid is centrifuged at 300 G for 15 minutes, the centrifugal supernatant is collected, heated to 37°C in a warm bath, and the liquid viscosity is measured using a viscometer, such as a vibration viscometer (VM-10A-H manufactured by Sekonic).

[0088] <Determination of the Presence or Absence of Aggregates> Aggregates were determined by visually inspecting the foam liquid. After allowing the collected foam liquid to stand, the presence or absence of aggregates was determined based on whether or not a precipitate formed.

[0089] The measurement results of the examples and comparative examples are shown in Table 1.

[0090]

[0091] 1 Sparger air supply pipe 2 Air supply pipe 3 Culture medium supply pipe 4 Exhaust pipe 5 Exhaust filter 6 Sampling pipe 7 Bleeding pipe 8 Capacitance sensor 9 Dissolved oxygen sensor 10 Cultivation vessel 11 Sparger 12 Stirring blade 13 Perfusion device 14 Flow of permeate 15 Culture medium supply pump 16 Delivery pump 17 Pressure gauge 18 Diaphragm pump 19 Foam

Claims

1. 30 x 10 in culture medium 6 cells / mL or more 400×10 6 A cell culture method for culturing cells at a cell density of 1000 cells / mL or less, comprising: a step A of adjusting the poloxamer concentration of a foam liquid constituting the foam to 6 times or less the poloxamer concentration in the culture medium; or a step B of adjusting the viscosity of the foam liquid constituting the foam to 1.5 mPa s or less under conditions of 35°C or higher and 38°C or lower.

2. The cell culture method according to claim 1, wherein step A is carried out when the poloxamer concentration in the foam liquid constituting the foam is 6 times or more the poloxamer concentration in the culture medium, or step B is carried out when the viscosity of the foam liquid constituting the foam is 1.5 mPa·s or more under conditions of 35°C to 38°C.

3. The cell culture method according to claim 1, wherein the poloxamer concentration in the culture medium is 1.5 g / L or more and 15 g / L or less.

4. The cell culture method according to claim 1, wherein step A or step B includes a step of aerating a gas into the culture medium.

5. The cross-sectional area of ​​the gas-liquid interface of the culture tank is S [cm 2 ], and the total amount of gas aeration into the culture medium is V [cm 3 5. The cell culture method according to claim 4, wherein H, S and V satisfy the relationship H / (V / S)<25 min, where H is the flow rate of the culture medium and V is the height of the foam layer.

6. The cross-sectional area of ​​the gas-liquid interface of the culture tank is S [cm 2 ], and the total amount of gas aeration into the culture medium is V [cm 3 5. The cell culture method according to claim 4, wherein, when the cell speed is set to a value of 0.3 cm / min < V / S < 9.4 cm / min, S and V satisfy the relationship: 0.3 cm / min < V / S < 9.4 cm / min.

7. The cell culture method according to any one of claims 1 to 6, wherein step A or step B comprises a step of spraying, dripping or sprinkling a liquid onto the foam.

8. A cell culture method according to any one of claims 1 to 6, wherein step A or step B includes a step of removing foam.

9. The cell culture method according to claim 8, wherein the step of removing foam is a step of eliminating or incorporating foam into the culture medium by rotating an agitator blade.

10. A method for producing a product, comprising carrying out the cell culture method according to any one of claims 1 to 6.

11. The method of claim 10, wherein the product is a protein.

12. 30 x 10 in culture medium 6 cells / mL or more 400×10 6 1. A method for producing a product, comprising culturing cells at a cell density of 1000 cells / mL or less, the method comprising: Step A: adjusting the poloxamer concentration of a foam liquid constituting the foam to 6 times or less the poloxamer concentration in the culture solution; or Step B: adjusting the viscosity of the foam liquid constituting the foam to 1.5 mPa s or less under conditions of 35°C or higher and 38°C or lower.

Citation Information

Patent Citations

  • Serum-free mammalian cell culture medium and uses thereof

    JP2000517188A

  • Method of expression

    JP2016517691A

  • Method for harvesting mammalian cell cultures

    JP7097404B2

  • Cell culture method, method for producing product, and cell culture device

    WO2020003833A1

  • Poloxamers for cell culture

    WO2022084386A1